Member Info for beinthelead

She’s not an employee. Her attachment should add value to the business while she’ll receive a fee for this service. She could live on the moon.

Has anyone got access to this study by Huang et al?

Huang, Sichao; Zhang, Yuchen; Zhong, Jinsong; Pan, Ying; Cai, Shaohui; Xu, Jun (2018). Toxicological profile and safety pharmacology of a single dose of fibroblast activation protein-a-based doxorubicin prodrug.

DOI: 10.1097/CAD.0000000000000593

Thanks.

https://twitter.com/Borg74/status/1504374033856573443?s=20&t=cJ7NwZ-T7MTIH_M8gAv6gA

How are these guys still peddling this rubbish?? We thought the trolls were bad.

I can see your logic - but in reality, it could well be a band aid. I don’t like all eggs in one basket. The diag biz is, in a lot of ways, more predictable than therapeutics. I’d rather see him place then sell it off.

Avacta’s USP is how diverse our investment is.

It’s all about the forward looking value, of which I believe, is far more valuable than £50m. It adds resilience in the event of failures within the threa division.

Are SNG more informative? Your narrative is futile. Honestly. Your ramping of other stocks that have clearly crashed gives you zero credibility in criticising Avacta’s future prospects.

Can’t believe Touk is still hanging around. He doesn’t even make the troll grade.

Thanks.

I’m still not seeing it. Conversely, I’d be cutting loss making (not soon/ever to be profitable) divisions to support others in the biz.

Wiggly - how so?

Cash plus slashing ongoing burden costs that we’re showing no signs of abating. This is more significant than small milestone payments we’ve seen in the past - £1m every year going forward.

Myles is pretty quiet these days, and I don’t blame him. Why would he need to pump to sell? He’s had months to offload.

Ophidian is dangerous.

Could it be the Vatic TT? Reality is we’re looking at a share that’s been beaten to a pulp. Not in the same league as ODX, yet has been dragged into the same mess. My guess is a rise on the sniff of Covid reappearing.

Give us a shout if you need any help. Few favours to repay :)

Timster - if it is, I’ll promise to be less grumpy :)

It’s click bait.

The market will baseline their view based on what is communicated in the RNS. It’ll be what it’ll be. Let’s start with some formal revenue figure and see where that takes us.

Aqueaus - thanks for pointing out where this was communicated. Belgrano implied it was not widely shared, hence my belief that it was rumour. Regardless, I’m not expecting a 4 month wait for stability.

Clovis are running a FAP targeted program, entering P1 trial. Worth a read, and a watch.

https://clovisoncology.com/pipeline/scientific-presentations/

Ah, thanks. I’m not interested in the rumour of course, only RNS communicated benchmarks. We should have a sales to date, and forecast. These should be inline, below, or exceeding expectations. Hoping for a positive forward look ahead.

Thanks Belgrano - I’m still not following. The results next week (as indicated) should include a forecast. The ‘soft launch’ has been known, therefore we should not fall short of a weak target?